AP3437A - Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis - Google Patents

Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis

Info

Publication number
AP3437A
AP3437A AP2011005849A AP2011005849A AP3437A AP 3437 A AP3437 A AP 3437A AP 2011005849 A AP2011005849 A AP 2011005849A AP 2011005849 A AP2011005849 A AP 2011005849A AP 3437 A AP3437 A AP 3437A
Authority
AP
ARIPO
Prior art keywords
pde4
modulations
tuberculosis
prevention
compositions
Prior art date
Application number
AP2011005849A
Other languages
English (en)
Other versions
AP2011005849A0 (en
Inventor
Gilla Kaplan
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3437(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AP2011005849A0 publication Critical patent/AP2011005849A0/xx
Application granted granted Critical
Publication of AP3437A publication Critical patent/AP3437A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005849A 2009-02-10 2010-02-09 Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis AP3437A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15146709P 2009-02-10 2009-02-10
PCT/US2010/023533 WO2010093588A1 (fr) 2009-02-10 2010-02-09 Méthodes d'utilisation et compositions comprenant des modulateurs de pde4 pour traiter, prévenir, et gérer la tuberculose

Publications (2)

Publication Number Publication Date
AP2011005849A0 AP2011005849A0 (en) 2011-08-31
AP3437A true AP3437A (en) 2015-10-31

Family

ID=42077260

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005849A AP3437A (en) 2009-02-10 2010-02-09 Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis

Country Status (23)

Country Link
US (1) US20120149716A1 (fr)
EP (2) EP2395995A1 (fr)
JP (2) JP2012517441A (fr)
KR (1) KR20110116049A (fr)
CN (1) CN102387798A (fr)
AP (1) AP3437A (fr)
AU (1) AU2010213936B2 (fr)
BR (1) BRPI1007500A2 (fr)
CA (1) CA2750123A1 (fr)
CO (1) CO6410289A2 (fr)
CR (1) CR20110411A (fr)
EA (1) EA201171035A1 (fr)
EC (1) ECSP11011295A (fr)
HK (1) HK1205681A1 (fr)
IL (1) IL214176A (fr)
MX (1) MX2011008132A (fr)
MY (1) MY160002A (fr)
NI (1) NI201100154A (fr)
NZ (1) NZ594193A (fr)
PE (2) PE20151143A1 (fr)
SG (2) SG173149A1 (fr)
UA (1) UA103791C2 (fr)
WO (1) WO2010093588A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2821805A1 (fr) 2010-12-16 2012-06-21 Celgene Corporation Formes posologiques pour des medicaments mediocrement solubles administres par voie orale a liberation controlee et leurs utilisations
AU2012308663B2 (en) 2011-09-14 2017-06-08 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
KR20210033073A (ko) 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
WO2013119607A2 (fr) * 2012-02-08 2013-08-15 Celgene Corporation Formulations à libération modifiée à base de (+)-2-[1-(3-éthoxy-4-méthoxy-phényl)-2-méthanesulfonyl-éthyl]-4-acétyl aminoisoindoline-1,3-dione
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
DE102018201827A1 (de) * 2017-02-28 2018-08-30 Aktiebolaget Skf Wälzlager
CN112220785B (zh) * 2020-09-22 2021-12-31 北京鑫开元医药科技有限公司 一种pde4抑制剂药物组合物及其制备方法与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045702A1 (fr) * 1999-12-21 2001-06-28 Celgene Corporation ACIDES ACYLHYDROXAMIQUES SUBSTITUES ET METHODE DE REDUCTION DES TAUX DE TNF$g(a)
WO2003080049A1 (fr) * 2002-03-20 2003-10-02 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions
WO2004043378A2 (fr) * 2002-11-06 2004-05-27 Celgene Corporation Procedes et compositions utilisant des medicaments d'inhibition selective de cytokine pour traiter et maitriser des cancers et d'autres maladies
WO2007108750A1 (fr) * 2006-03-22 2007-09-27 Astrazeneca Ab Dérivés de pyridopyrimidine et leur utilisation comme inhibiteurs de pde4

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
JPH09505082A (ja) * 1994-03-09 1997-05-20 ファイザー・インコーポレーテッド Ｔｎｆ放出の阻害剤としてのイソオキサゾリン
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
ATE418536T1 (de) 1996-08-12 2009-01-15 Celgene Corp Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel
ATE238052T1 (de) 1997-07-31 2003-05-15 Celgene Corp Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
TR200200966T1 (tr) * 2000-08-09 2002-09-23 Panacea Biotec Limited Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri
AU2003222034A1 (en) 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20040167199A1 (en) 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7173058B2 (en) 2002-12-30 2007-02-06 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
AU2004218364A1 (en) 2003-03-05 2004-09-16 Celgene Corporation Diphenylethylene compounds and uses thereof
ATE508114T1 (de) 2003-03-12 2011-05-15 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
JP4713465B2 (ja) 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
US7244259B2 (en) 2003-10-31 2007-07-17 Ethicon, Inc. Guide for surgical device for the treatment of urinary incontinence
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
JP2008523102A (ja) * 2004-12-13 2008-07-03 セルジーン・コーポレーション Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045702A1 (fr) * 1999-12-21 2001-06-28 Celgene Corporation ACIDES ACYLHYDROXAMIQUES SUBSTITUES ET METHODE DE REDUCTION DES TAUX DE TNF$g(a)
WO2003080049A1 (fr) * 2002-03-20 2003-10-02 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions
WO2004043378A2 (fr) * 2002-11-06 2004-05-27 Celgene Corporation Procedes et compositions utilisant des medicaments d'inhibition selective de cytokine pour traiter et maitriser des cancers et d'autres maladies
WO2007108750A1 (fr) * 2006-03-22 2007-09-27 Astrazeneca Ab Dérivés de pyridopyrimidine et leur utilisation comme inhibiteurs de pde4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARRIOTT J B ET AL: "CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 OCT 1998 LNKD- PUBMED:9780198, vol. 161, no. 8, 15 October 1998 (1998-10-15), pages 4236-4243 *

Also Published As

Publication number Publication date
JP2015164928A (ja) 2015-09-17
NI201100154A (es) 2012-01-24
SG10201402158VA (en) 2014-07-30
PE20120580A1 (es) 2012-05-23
HK1205681A1 (en) 2015-12-24
EA201171035A1 (ru) 2012-02-28
AU2010213936B2 (en) 2014-07-31
PE20151143A1 (es) 2015-08-07
AP2011005849A0 (en) 2011-08-31
AU2010213936A1 (en) 2011-08-11
JP2012517441A (ja) 2012-08-02
KR20110116049A (ko) 2011-10-24
NZ594193A (en) 2013-09-27
US20120149716A1 (en) 2012-06-14
BRPI1007500A2 (pt) 2016-02-16
IL214176A0 (en) 2011-08-31
ECSP11011295A (es) 2011-09-30
WO2010093588A1 (fr) 2010-08-19
CR20110411A (es) 2012-01-06
MY160002A (en) 2017-02-15
CN102387798A (zh) 2012-03-21
SG173149A1 (en) 2011-08-29
IL214176A (en) 2016-09-29
CA2750123A1 (fr) 2010-08-19
UA103791C2 (uk) 2013-11-25
EP2395995A1 (fr) 2011-12-21
MX2011008132A (es) 2011-09-06
EP2818164A1 (fr) 2014-12-31
CO6410289A2 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
AP3437A (en) Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis
EP2614369A4 (fr) Inhibiteurs de l'ezh2 humaine, et leurs procédés d'utilisation
HK1194071A1 (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2640395A4 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
EP2303193A4 (fr) Dispositifs et procédés pour le traitement de facette et d autres articulations
IL217340A0 (en) Devices and methods for tissue engineering
EP2262450A4 (fr) Implants et procédés d utilisation
EP2293800A4 (fr) Compositions et procédés pour le traitement de troubles de l'oreille
EP2361089A4 (fr) Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine
IL218663A0 (en) Devices and methods for tissue engineering
ME01883B (me) Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa
EP2326375A4 (fr) Dispositifs et procédés permettant de réduire au minimum et de traiter le mal d altitude
EP2519290A4 (fr) Procédés, dispositifs, et compositions d'auto-mélange dentaire
EP2429584A4 (fr) Procédés et compositions de traitement
EP2164978A4 (fr) Compositions et procédés pour moduler l'activité d'adamts13
EP2640391A4 (fr) Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
HK1193379A1 (en) Remedial composition and treatment methods
EP2300495A4 (fr) Solutions utilisables en ingénierie tissulaire et leurs procédés d'utilisation
EP2437771A4 (fr) Compositions et procédés modulant mg29 pour le traitement du diabète
EP2300044A4 (fr) Procédés et compositions pour la prise en charge de la douleur à base d' oméga-conotoxines
HK1136303A1 (en) Formulation and use of ergosta-7,22-dien-3-ol -722--3-
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
IL209658A0 (en) Compositions and methods for treatment of ear disorders